Sensulin LLC is a preclinical biopharmaceutical company based in Oklahoma City, OK. They are focused on developing a glucose-responsive insulin for both type 1 and type 2 diabetes, aiming to reduce the risk of hypoglycemia and long-term complications associated with the disease, while also minimizing the number of daily injections required.
Their ultimate goal is to eliminate the need for separate basal and mealtime insulin, offering a significant improvement in standard care and providing those with diabetes the opportunity for a normal life. With a team of experienced executives and a commitment to innovation, Sensulin is dedicated to transforming the treatment of diabetes and improving the lives of patients.
Generated from the website